XML 38 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
12. Segments
 6 Months Ended
Sep. 30, 2015
Segment Reporting [Abstract]  
12. Segments

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

 

The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:

 

   Six Months Ended September 30, 
   2015   2014 
Revenues:          
Aethlon  $380,874   $530,371 
ESI   –    – 
Total Revenues  $380,874   $530,371 
           
Operating Losses:          
Aethlon  $(1,911,219)  $(1,294,453)
ESI   (303,113)   (445,674)
Total Operating Loss  $(2,214,332)  $(1,773,200)
           
Net Losses:          
Aethlon  $(2,165,152)  $(4,202,873)
ESI   (303,113)   (356,539)
Net Loss Before Non-Controlling Interests  $(2,468,265)  $(4,592,485)
           
Cash:          
Aethlon  $4,208,554   $47,865 
ESI   802    478,322 
Total Cash  $4,209,356   $526,187 
           
Total Assets:          
Aethlon  $4,677,989   $443,027 
ESI   27,486    646,242 
Total Assets  $4,705,475   $1,089,269 
           
Capital Expenditures:          
Aethlon  $–   $– 
ESI   –    – 
Capital Expenditures  $–   $– 
           
Depreciation and Amortization:          
Aethlon  $8,886   $8,885 
ESI   9,790    9,791 
Total Depreciation and Amortization  $18,676   $18,676 
           
Interest Expense:          
Aethlon  $(253,933)  $(144,799)
ESI   –    – 
Total Interest Expense  $(253,933)  $(144,799)